Atria Investments LLC increased its position in shares of Biogen Inc (NASDAQ:BIIB) by 25.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,756 shares of the biotechnology company’s stock after purchasing an additional 950 shares during the period. Atria Investments LLC’s holdings in Biogen were worth $1,515,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in the stock. Nisa Investment Advisors LLC raised its holdings in Biogen by 0.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 88,943 shares of the biotechnology company’s stock worth $28,335,000 after purchasing an additional 650 shares in the last quarter. Broadleaf Partners LLC bought a new stake in Biogen during the fourth quarter worth approximately $2,537,000. Rockland Trust Co. bought a new stake in Biogen during the fourth quarter worth approximately $257,000. LGT Capital Partners LTD. raised its holdings in Biogen by 7.7% during the fourth quarter. LGT Capital Partners LTD. now owns 37,890 shares of the biotechnology company’s stock worth $12,071,000 after purchasing an additional 2,720 shares in the last quarter. Finally, Country Trust Bank raised its holdings in Biogen by 2.8% during the fourth quarter. Country Trust Bank now owns 108,588 shares of the biotechnology company’s stock worth $34,593,000 after purchasing an additional 2,978 shares in the last quarter. 88.14% of the stock is currently owned by hedge funds and other institutional investors.
Biogen Inc (NASDAQ:BIIB) opened at $342.41 on Friday. Biogen Inc has a 52-week low of $244.28 and a 52-week high of $348.84. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.90 and a current ratio of 2.19. The firm has a market cap of $72,410.00, a P/E ratio of 20.99, a price-to-earnings-growth ratio of 1.96 and a beta of 0.73.
Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Tuesday, October 24th. The biotechnology company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.70 by $0.61. Biogen had a net margin of 29.44% and a return on equity of 38.51%. The firm had revenue of $3.08 billion for the quarter, compared to analysts’ expectations of $3.05 billion. During the same period in the previous year, the company posted $5.19 EPS. The company’s quarterly revenue was up 4.1% compared to the same quarter last year. equities analysts anticipate that Biogen Inc will post 22 earnings per share for the current year.
In other news, CEO Michel Vounatsos acquired 780 shares of the stock in a transaction on Saturday, December 29th. The shares were purchased at an average cost of $320.55 per share, for a total transaction of $250,029.00. Following the transaction, the chief executive officer now owns 4,879 shares in the company, valued at approximately $1,563,963.45. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Alexander J. Denner acquired 30,000 shares of the stock in a transaction on Wednesday, November 29th. The shares were purchased at an average price of $317.36 per share, for a total transaction of $9,520,800.00. Following the completion of the transaction, the director now owns 10,029 shares in the company, valued at approximately $3,182,803.44. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 31,560 shares of company stock worth $10,020,858. Corporate insiders own 0.25% of the company’s stock.
Several equities research analysts recently commented on the company. Mizuho reissued a “buy” rating and set a $400.00 target price on shares of Biogen in a report on Thursday. Canaccord Genuity set a $350.00 price target on Biogen and gave the company a “hold” rating in a report on Tuesday. Citigroup reaffirmed an “outperform” rating and issued a $380.00 price target (up previously from $350.00) on shares of Biogen in a report on Tuesday. Oppenheimer set a $380.00 price target on Biogen and gave the company a “buy” rating in a report on Monday, January 15th. Finally, BidaskClub raised Biogen from a “hold” rating to a “buy” rating in a report on Friday, January 5th. Nine investment analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $353.75.
ILLEGAL ACTIVITY WARNING: “Biogen Inc (BIIB) Position Raised by Atria Investments LLC” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/01/20/biogen-inc-biib-position-raised-by-atria-investments-llc.html.
Biogen Company Profile
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc (NASDAQ:BIIB).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.